Share this Product
Recommended use or purpose:
Smoking cessation aid.
Day 1 to 3: 1 every 2 hours; 6 tablets (9 mg) daily.
Day 4 to 12: 1 every 2.5 hours; 5 tablets (7.5 mg) daily.
Day 13 to 16: 1 every 3 hours; 4 tablets (6 mg) daily.
Day 17 to 20: 1 every 4 hours; 3 tablets (4.5 mg) daily.
Day 21 to 25: 1 every 6 hours; 2 tablets (3 mg) daily.
Keep out of reach of children. Some people may experience changes in both taste and appetite, dryness in the mouth, headache, irritability, nausea, constipation, tachycardia, light elevation of the arterial pressure.
Consult a health care practitioner prior to use if you have hyperthyroidism; if you have an ulcer, ischemic heart disease, cardiac impairment, cerebrovascular disease, high blood pressure, renal or hepatic insufficiency; if you have diabetes mellitus; or if you have a history of psychiatric disorders or if you experience psychological distress.
Symptoms of an overdose include nausea, abdominal pain, vomiting, diarrhea, cold sweat, dizziness, disturbed hearing and vision, mental confusion, rapid heartbeat, difficulty breathing and marked weakness. May cause sleep disorders.
Do not use if you have arterial hypertension and advanced atherosclerosis. Do not use if you are pregnant or breastfeeding.
Simultaneous administration of cytisine and smoking could lead to nicotine intoxication.
Ingredients (per capsule):
Cytisine (isolate from Cytisus laborinum L.).......1.5 mg
Microcrystalline cellulose, silicon dioxide, L-leucine, pullulan/hypromellose (capsule)
- Han J, Wang DS, Liu SB, Zhao MG. Cytisine, a partial agonist of a4b2 nicotinic acetylcholine receptors, reduced unpredictable chronic mild stress-induced depression-like behaviors. Biomol Ther (2016). 24(3):291-297
- Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56–63
- Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens JW, Strong M, Cantrell A. What is the clinical effectiveness and cost-effectiveness of cytosine compared with varenicline for smoking cessation? A systematic review and economic evaluation. Health Technol Assess 2014;18(33).
- Schmidt F. Medikamentose Unterstutzung der Raucherentwohnung: Bericht uber Versuche an uber 500 Rauchern im Doppelblindversuch. MMW Munch Med Wochenschr 1974;116:557–64.
*VitaAid is offered available through professional clinician only.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.